I-Mab Biopharma

I-Mab Biopharma company information, Employees & Contact Information

Explore related pages

I-Mab Biopharma email format I-Mab Biopharma management contacts

Related company profiles:

I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company’s differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain a strong tumor-binding property and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with CLDN18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents. I-Mab also recently announced that new data on givastomig has been accepted for a Mini Oral presentation at the European Society of Medical Oncology Gastrointestinal Cancers Congress 2025, scheduled for July 2, 2025, in Barcelona, Spain.

Company Details

Employees
117
Founded
-
Address
2440 Research Blvd,
Phone
862160578000
Email
ma****@****rma.com
Industry
Biotechnology
Website
i-mabbiopharma.com
Keywords
Biopharmaceutical, Antibody, Immuno-oncology, Biologics, Drug Development, Cancer, Bispecific antibodies, Monoclonal antibodies.
HQ
Rockville, Maryland
Competitors
Vesalius Therapeutics, Sangamo Therapeutics, Inc., Muna Therapeutics, ABL Bio Inc., Shanghai Junshi Biosciences Co Ltd, ABio-X, Innovent Biologics, Zentalis Pharmaceuticals, Allakos Inc, Zai Lab.
Looking for a particular I-Mab Biopharma employee's phone or email?

I-Mab Biopharma Questions

News

I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers - Yahoo Finance

I-Mab Completes Enrollment in Planned Phase 1b Dose Expansion Study for Givastomig in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers Yahoo Finance

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee - Yahoo Finance

I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee Yahoo Finance

I-Mab Signs Agreement to Divest its Assets and Business Operations in China - PR Newswire

I-Mab Signs Agreement to Divest its Assets and Business Operations in China PR Newswire

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health - GlobeNewswire

I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health GlobeNewswire

I-Mab Reports Full Year 2023 Financial Results and Business Update - PR Newswire

I-Mab Reports Full Year 2023 Financial Results and Business Update PR Newswire

I-Mab to Present Short-Talk on Updated Givastomig - GlobeNewswire

I-Mab to Present Short-Talk on Updated Givastomig GlobeNewswire

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments - Yahoo Finance

I-Mab Announces Acceleration of Givastomig Investment and Leadership Appointments Yahoo Finance

I-Mab Reports Third Quarter 2024 Results - PR Newswire

I-Mab Reports Third Quarter 2024 Results PR Newswire

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update Yahoo Finance

I-Mab Announces Closing of the Divestiture of Business Operations in China - PR Newswire

I-Mab Announces Closing of the Divestiture of Business Operations in China PR Newswire

I-Mab Biopharma Expands Global Team, Appoints Neil K. Warma As General Manager of I-Mab U.S. - PR Newswire

I-Mab Biopharma Expands Global Team, Appoints Neil K. Warma As General Manager of I-Mab U.S. PR Newswire

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance

I-Mab Regains Compliance with Nasdaq Minimum Bid Price Requirement Yahoo Finance

I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center - PR Newswire

I-Mab Biopharma and Jiangsu Nhwa Pharmaceutical Announce Strategic Collaboration Agreement with Biodextris and a Boston-Based, Leading Academic Medical Center PR Newswire

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences - Yahoo Finance

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences Yahoo Finance

I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium - PR Newswire

I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium PR Newswire

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 - Yahoo Finance

I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025 Yahoo Finance

I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board - PR Newswire

I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board PR Newswire

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China - PR Newswire

I-Mab Announces First Patient Dosed in Phase 3 Registrational Study of CD47 Antibody Lemzoparlimab in MDS in China PR Newswire

I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies - PR Newswire

I-Mab Biopharma and ABL Bio Announce Global Collaboration on Innovative Bispecific Antibodies PR Newswire

I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa - PR Newswire

I-Mab and Jumpcan Announce Strategic Commercial Partnership on Eftansomatropin Alfa PR Newswire

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency - PR Newswire

I-Mab Announces Completion of Patient Enrollment in Phase III Clinical Trial of Eftansomatropin alfa for Treatment of Pediatric Growth Hormone Deficiency PR Newswire

I-Mab —A Biotech on the Rise with Inspired Science - Endpoints News

I-Mab —A Biotech on the Rise with Inspired Science Endpoints News

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 - PR Newswire

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 PR Newswire

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 - PR Newswire

I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503 PR Newswire

I-Mab Biopharma Signs Licensing Agreement for HyLeukin With Genexine - PR Newswire

I-Mab Biopharma Signs Licensing Agreement for HyLeukin With Genexine PR Newswire

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis - PR Newswire

I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis PR Newswire

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - GlobeNewswire

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement GlobeNewswire

I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors - PR Newswire

I-Mab Announces IND Approval from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors PR Newswire

I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease - PR Newswire

I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer's Disease PR Newswire

I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China - PR Newswire

I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China PR Newswire

I-Mab Added to MSCI China Index - PR Newswire

I-Mab Added to MSCI China Index PR Newswire

I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board - PR Newswire

I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board PR Newswire

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) - PR Newswire

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN) PR Newswire

I-Mab Biopharma : and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma - MarketScreener

I-Mab Biopharma : and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Study of TJ202/MOR202 in Multiple Myeloma MarketScreener

Companies like I-Mab Biopharma

ABL Bio Inc. logo - Similar company to I-Mab Biopharma

Abl Bio Inc.

59
ABio-X logo - Similar company to I-Mab Biopharma

Abio-X

11
Zai Lab logo - Similar company to I-Mab Biopharma

Zai Lab

533
Allakos Inc logo - Similar company to I-Mab Biopharma

Allakos Inc

41
Sangamo Therapeutics, Inc. logo - Similar company to I-Mab Biopharma

Sangamo Therapeutics...

267
Shanghai Junshi Biosciences Co Ltd logo - Similar company to I-Mab Biopharma

Shanghai Junshi Bios...

214
Muna Therapeutics logo - Similar company to I-Mab Biopharma

Muna Therapeutics

56
Vesalius Therapeutics logo - Similar company to I-Mab Biopharma

Vesalius Therapeutics

36
Zentalis Pharmaceuticals logo - Similar company to I-Mab Biopharma

Zentalis Pharmaceuti...

129
Innovent Biologics logo - Similar company to I-Mab Biopharma

Innovent Biologics

832

Top I-Mab Biopharma Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant